Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. META
6. MU
7. BLZE
8. PRIM
9. ACN
10. NVDA

Go back to Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
(NASDAQ: FULC) Delayed: 3.85 +0.08 (2.12%)
Previous Close $3.77    52 Week High $ 
Open $3.69    52 Week Low $ 
Day High $3.89    P/E N/A 
Day Low $3.69    EPS $ 
Volume 2,813,529